Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.

@article{Jassem2008PhaseIT,
  title={Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.},
  author={Jacek Jassem and Rodryg Adam Ramlau and Armando Santoro and Wolfgang Schuette and Assad Chemaissani and Shengyan Hong and Johannes Blatter and Susumu Adachi and Axel R. Hanauske and Christian Manegold},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 10},
  pages={1698-704}
}
PURPOSE This multicenter, phase III study compared overall survival (OS) of second-line pemetrexed plus best supportive care (BSC) versus BSC alone in patients with advanced malignant pleural mesothelioma (MPM). Secondary end points included response rate, progression-free survival (PFS), time to tumor progression (TTP), time to treatment failure (TTF), and toxicity. PATIENTS AND METHODS Patients with relapsed MPM after first-line chemotherapy were randomly assigned to receive pemetrexed 500… CONTINUE READING